- FDA’s QSR/GMPs – 21 CFR Parts 820, 210 & 211, 600, 806, 58, 7, and 11, 803, 806,
- QSIT Mock Inspections
- Root Cause Analysis and CAPA
- Post-Market Surveillance and Vigilance
- ISO 13885, 9001:2015, 14971
- MDD/IMDD requirements
- MHLW Ministerial Ordinance no. 169
- Health Canada Medical Device Regulations
- Quality Engineering
- Design Control
- Design Dossier Reviews
- Technical Files Compilation
- ERES and Documentation Systems
- Complaint Handling
- HIPAA requirements
- Process Validation
- CE-Marking
- Post Market surveillance and Vigilance programs
- Quality Systems and Systems-based Implementation & Auditing
- Process Validation
- Supplier Quality Agreements
- Quality Engineering
- Mock FDA inspections
- Risk Management / hazard analysis
- Process Improvement
- Lean Manufacturing and Six-sigma
|
- Compliance Master Plan remediation
- Facilitating responses to address FDA-483s and Warning Letters
- Product Registrations
- Pre-Approval and Readiness Assessments
- CAPA remediation
- Complaint Handling and MDR remediation
- Pharmaceutical, and Biologics Industries
- Facilitating responses to address FDA-483s and Warning Letters
- ERES and Documentation Systems
- Quality Assurance and Audits
- Quality Systems and Systems-based Implementation & Auditing
- OTC Cosmetics
- Aseptic audits & Aseptic operations
- Cleaning Validation
- Regulatory Compliance
- Failure Investigation and OOS
- Deviation Handling
- Equipment qualification
- Documentation Systems
- cGMPs, GCP, GLP Training
- Supplier Quality Assurance
- Analytical method validation
- Change control programs
- sterility assurance
- Pharmacy Compounding Audits
- USP 797
- GLP Laboratory
|